Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II

Launched by FAZAIA RUTH PFAU MEDICAL COLLEGE · Nov 25, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called Empagliflozin on the quality of life for patients who have both chronic heart failure and type II diabetes. The goal is to see how this treatment can help improve everyday living for patients in Pakistan, taking into account their unique genetic and cultural backgrounds. The study not only aims to assess the benefits of Empagliflozin but also to explore if it can be a cost-effective option for managing both chronic heart failure and diabetes, which could help lessen the financial strain on patients and the healthcare system.

To participate in this trial, individuals need to be between 40 and 70 years old, have chronic heart failure classified as class II to IV (meaning their condition ranges from mild to severe), and have a specific type of heart function issue. They must also have diabetes and be using diabetes medications. The trial is currently looking for participants, and those who join can expect to be closely monitored and supported throughout the study. It’s important to note that certain individuals, such as pregnant women or those with severe kidney problems, cannot participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 40-70 years at time of screening.
• • 2. Both Men and women are included in study.
• • 3. Patients with chronic heart failure and currently categorized in class II-IV heart failure as per NHYA classification having ejection fraction less than 40%.
• • 4. Patients having NT- proBNP levels greater than 25pg/ml.
• • 5. Diabetic patient diagnosed (HbA1c \> 6.5mg/dl) and currently taking antidiabetic medicine.
• Exclusion Criteria:
• • 1. Pregnant female.
• • 2. Patient with end stage renal disease (ESRD).
• • 3. Patient with acute decompensated heart failure.
• • 4. Acute coronary syndrome patients.